AU2003300414A8 - Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers - Google Patents

Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Info

Publication number
AU2003300414A8
AU2003300414A8 AU2003300414A AU2003300414A AU2003300414A8 AU 2003300414 A8 AU2003300414 A8 AU 2003300414A8 AU 2003300414 A AU2003300414 A AU 2003300414A AU 2003300414 A AU2003300414 A AU 2003300414A AU 2003300414 A8 AU2003300414 A8 AU 2003300414A8
Authority
AU
Australia
Prior art keywords
bcl
disorder
treatment
methods
antisense oligomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003300414A
Other versions
AU2003300414A1 (en
Inventor
Raymond P Warrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genta Inc
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/738,717 external-priority patent/US20040147473A1/en
Priority claimed from US10/738,867 external-priority patent/US7855183B2/en
Application filed by Genta Inc filed Critical Genta Inc
Publication of AU2003300414A1 publication Critical patent/AU2003300414A1/en
Publication of AU2003300414A8 publication Critical patent/AU2003300414A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU2003300414A 2002-12-19 2003-12-19 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers Abandoned AU2003300414A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US43502902P 2002-12-19 2002-12-19
US43505702P 2002-12-19 2002-12-19
US60/435,057 2002-12-19
US60/435,029 2002-12-19
US10/738,717 US20040147473A1 (en) 2000-11-10 2003-12-16 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US10/738,717 2003-12-16
US10/738,867 2003-12-16
US10/738,867 US7855183B2 (en) 2000-11-10 2003-12-16 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
PCT/US2003/041433 WO2004056971A2 (en) 2002-12-19 2003-12-19 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Publications (2)

Publication Number Publication Date
AU2003300414A1 AU2003300414A1 (en) 2004-07-14
AU2003300414A8 true AU2003300414A8 (en) 2004-07-14

Family

ID=32686284

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003300414A Abandoned AU2003300414A1 (en) 2002-12-19 2003-12-19 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Country Status (2)

Country Link
AU (1) AU2003300414A1 (en)
WO (1) WO2004056971A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018911A1 (en) * 2004-01-12 2006-01-26 Dana Ault-Riche Design of therapeutics and therapeutics
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US20060135455A1 (en) * 2004-06-01 2006-06-22 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
WO2007064857A2 (en) 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Amphoteric liposome formulation
EP3000480A1 (en) * 2005-12-01 2016-03-30 ProNAi Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2010043582A1 (en) * 2008-10-17 2010-04-22 Santaris Pharma A/S Method for the treatment of cancer
JP2016509572A (en) * 2012-11-05 2016-03-31 プロナイ セラピューティクス インコーポレイテッド Methods of using biomarkers for the treatment of cancer by modulating BCL2 expression
SI3319995T1 (en) 2015-07-07 2019-07-31 F. Hoffmann-La Roche Ag Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor
US20180221393A1 (en) 2015-08-03 2018-08-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects

Also Published As

Publication number Publication date
WO2004056971A3 (en) 2005-03-10
AU2003300414A1 (en) 2004-07-14
WO2004056971A2 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AU8837301A (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
GB2382344B (en) Wastewater treatment
AU2003280004A8 (en) Hair treatment method
GB0512560D0 (en) Bioreactors for well treatment
GB0129976D0 (en) Treatment method
AU2003300414A8 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
HUP0400032A3 (en) Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
IL161005A0 (en) Neuroprotective treatment methods using selective inos inhibitors
GB0124124D0 (en) Methods of treatment
EP1389105A4 (en) Method of treatment
SG89379A1 (en) Treatment apparatus
GB0105899D0 (en) Fibrosis reduction treatment
GB0130763D0 (en) Treatment methods
GB0026838D0 (en) Treatment method
GB2394656B (en) Hair treatment apparatus
EP1303281A4 (en) Methods of treatment
GB2397308B (en) Fibre treatment and conveyor apparatus
GB0126253D0 (en) Treatment method
GB0211297D0 (en) Pain treatment
GB2413798B (en) Bioreactors for well treatment
GB0130694D0 (en) Treatment
GB0102927D0 (en) Treatment method
GB0031272D0 (en) Diamond treatment
GB0009490D0 (en) Diamond treatment
GB0119173D0 (en) Pain treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase